VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

27 6 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies Healthcare Conference

24 5 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 5 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

02 5 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

25 4 2023 02:00:00 提供 Nasdaq GlobeNewswire

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

10 4 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

07 3 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

21 2 2023 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

20 12 2022 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD

19 12 2022 16:01:00 提供 Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

09 11 2022 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Announces November 2022 Investor Conference Participation

02 11 2022 03:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

26 10 2022 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

17 10 2022 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

14 10 2022 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

29 8 2022 02:00:00 提供 Nasdaq GlobeNewswire

Verona Pharma strengthens commercialization leadership team

24 8 2022 02:00:00 提供 Nasdaq GlobeNewswire

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

19 8 2022 02:46:07 提供 Nasdaq GlobeNewswire

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

15 8 2022 16:05:00 提供 Nasdaq GlobeNewswire

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

10 8 2022 20:22:20 提供 Nasdaq GlobeNewswire